Introduction
============

As an important part of the immune system, antimicrobial peptides (AMPs) can physically destroy microbial membranes and induce their cleavage, indicating their potential as substitutes for traditional antibiotics ([@b1-mmr-21-01-0061]). Following the identification of LL-37, the only natural human cathelicidin (an AMP subfamily), in 1995 ([@b2-mmr-21-01-0061],[@b3-mmr-21-01-0061]), its presence has been detected in various types of cells and epithelia, including intestinal epithelial cells ([@b4-mmr-21-01-0061]), mast cells ([@b5-mmr-21-01-0061]), monocytes ([@b6-mmr-21-01-0061]) and lymphocytes ([@b7-mmr-21-01-0061]). Natural human AMPs are the first line of defense against local infection, serving an important role in the invasion of systemic pathogens into local areas or local wound infections ([@b8-mmr-21-01-0061],[@b9-mmr-21-01-0061]). As the peptide chain of LL-37 is too long and difficult to synthesize, it is not a routine therapeutic drug for bacterial infections or other inflammatory diseases in the clinic; however, the cost of producing short-chain AMPs is relatively low. Furthermore, the removal of hydrophobic amino acids from the N-terminus of natural LL-37 can reduce its toxicity to eukaryotic cells, as well as reduce its interactions with human plasma proteins ([@b10-mmr-21-01-0061],[@b11-mmr-21-01-0061]). Thus, short-chain AMPs have attracted the attention of researchers. Compared with natural LL-37, KR-20 and KS-30, two derivatives of LL-37, exhibit improved antimicrobial properties ([@b12-mmr-21-01-0061],[@b13-mmr-21-01-0061]). KR-12 is the shortest derivative of LL-37 with antimicrobial activity ([@b10-mmr-21-01-0061],[@b11-mmr-21-01-0061]). Compared with LL-37 and its other derivatives, the cost of KR-12 synthesis is lower, and its cytotoxicity is reduced; for example, LL-37, but not KR-12, induces hemolytic effectsin human erythrocytes ([@b14-mmr-21-01-0061]). As an analogue of KR-12 (amino acid sequence: KRIVQRIKDFLR-NH~2~), KR-12-a6 (amino acid sequence: LRIVKLILKWLR-NH~2~) has similar antibacterial properties and biocompatibility ([@b15-mmr-21-01-0061]); also, as a highest hydrophobic analogue of KR-12, KR-12-a6 displays greater inhibition of lipopolysaccharide (LPS)-stimulated tumor necrosis factor-α production and higher LPS-binding activity than KR-12 ([@b15-mmr-21-01-0061]). Therefore, KR-12-a6 may be a potential therapeutic drug for the treatment of clinical infectious diseases, including osteomyelitis.

Osteomyelitis is a common infectious disease that can cause serious symptoms locally or systemically, such as severe pain, high fever, swelling and tenderness around the infection site, posing a great challenge to clinical treatment ([@b16-mmr-21-01-0061]). In addition to the surgical removal of infected bone tissues, local or systemic application of antibiotics is the most common treatment ([@b17-mmr-21-01-0061]); however, with the increasing use of antibiotics to treat bone infections in the clinic, bacterial resistance to antibiotics has gradually developed ([@b18-mmr-21-01-0061]). In addition, osteolysis caused by infection cannot be treated with traditional antibiotics. Gentamicin ([@b19-mmr-21-01-0061]) and vancomycin ([@b20-mmr-21-01-0061]), two commonly used antibiotics in the treatment of bone-related infections, have been shown to inhibit the viability of osteoblasts and reduce their numbers. Recently, certain small polypeptides have been reported to promote bone integration while controlling infection ([@b21-mmr-21-01-0061]). Therefore, drugs with favorable antibacterial properties and pro-osseointegration abilities are of great importance for the treatment of clinical bone infections.

Human bone marrow mesenchymal stem cells (hBMSCs) play a key role in the process of bone regeneration ([@b22-mmr-21-01-0061]--[@b24-mmr-21-01-0061]). hBMSCs can differentiate into osteoblasts during bone formation, and are the main source of bone progenitor cells ([@b25-mmr-21-01-0061]). When local infections are controlled, hBMSCs are activated and differentiate into osteoblasts to repair the local osteolysis ([@b26-mmr-21-01-0061]). However, when hBMSCs fail to completely repair the local bone defect caused by infection, local osteoporosis and even pathological fracture can result ([@b27-mmr-21-01-0061]). At present, drugs that inhibit osteoclast activity and bone resorption, such as vitamin D analogues, calcitonin and estrogen, are commonly used in the treatment of osteoporosis ([@b28-mmr-21-01-0061]). However, these drugs do not promote osteogenic differentiation or exhibit antibacterial properties. Considering the increased resistance to antibiotics in the clinic and the ideal antibacterial properties of AMPs, it was proposed that AMPs may exhibit positive therapeutic effects for the treatment of osteomyelitis ([@b29-mmr-21-01-0061]). Therefore, the present study examined whether its analogue KR-12-a6 could also promote the osteogenic differentiation of hBMSCs and investigated the underlying mechanisms.

Materials and methods
=====================

### Isolation and culture of hBMSCs

Bone marrow was obtained from the iliac crest marrow aspirates of 3 healthy donors (one 34-year old male, two females at 19 and 38-year\'s old) undergoing iliac crest bone transplantation at Jingzhou Central Hospital, Tongji Medical College of Huazhong University of Science and Technology (Jingzhou, China) between January and July 2018. The procedure was performed following approval from the Ethics Committee of Huazhong University of Science and Technology and after obtaining donors\' informed consent. The collected bone marrow was treated with heparin anticoagulant and then diluted in α-minimal essential medium (α-MEM; Gibco; Thermo Fisher Scientific, Inc.) ([@b30-mmr-21-01-0061]). hBMSCs were then isolated by density gradient centrifugation (400 × g for 20 min at room temperature) with Ficoll-Paque (GE Healthcare) and plastic adherence, purified by discarding suspended cells through exchanging medium, and then grown in α-MEM supplemented with 20% fetal bovine serum (Atlanta Biologicals; Bio-Techne Corporation), 100 U/ml penicillin (Invitrogen; Thermo Fisher Scientific, Inc.), 100 µg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.), and 2 mM L-glutamine (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were then cultured at 37°C with 5% humidified CO~2~. The hBMSCs were passaged and maintained at low density. Adherent cells reaching 80% confluence were harvested by using 0.25% trypsin at 37°C for 3 min. Then, 1×10^5^ cells were replated, and the remainder was used for the analysis of gene expression.

### Osteoblast differentiation

hBMSCs were plated in 6-well plates in standard growth medium. At 80% confluence, the medium was replaced with osteogenic medium consisting of α-MEM + 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin supplemented with 10 mM β-glycerophosphate (Calbiochem; Merck KGaA), 50 *µ*g/ml L-ascorbic acid (Wako Chemicals GmbH), 10 nM dexamethasone (Sigma-Aldrich; Merck KGaA), and 10 nM calcitriol (Sigma-Aldrich; Merck KGaA). The medium was replaced every 3 days. The control cells were grown in standard growth medium. Cell pellets were harvested for RNA isolation at different time points following induction.

### Alkaline phosphatase (ALP) staining and quantitative analysis

hBMSCs were cultured in 24-well plates at 2×10^4^ cells/cm^2^. At 80% confluence, cells were induced to differentiate into osteoblasts using StemPro™ Osteogenesis Differentiation kit (Gibco; Thermo Fisher Scientific, Inc.) supplemented with KR-12-a6 (synthesized and purified by GL Biochem (Shanghai) Ltd.) at 0, 20, 30, 40, 60, or 80 *µ*g/ml at 37°C for 7 days. For ALP staining, hBMSCs in each group were washed twice with PBS at the end of the 7-day KR-12-a6-treatment period, fixed with 4% paraformaldehyde for 30 s, and then stained using the ALP staining kit (Maokang Biotechnology, Shanghai) according to the manufacturer\'s instructions. Images were acquired by an inverted phase contrast microscope (CKX41, Olympus) under ×100 magnification. At least five fields per sample were randomly selected and observed. To quantitatively analyze ALP activity, hBMSCs after the 7-day KR-12-a6-treatment period were washed twice with PBS and lysed with Triton X-100 (1%) for 15 min. Then, the activity was measured by Alkaline Phosphatase Assay kit (Beyotime Institute of Biotechnology) according to the manufacturer\'s instructions. The final estimation was based on the absorbance at 405 nm measured by a spectrophotometer.

### Alizarin red staining and quantitative analysis

Assessment of *ex vivo* mineralization was performed by employing alizarin red staining. hBMSCs at the density of 5×10^4^ cells/well in 6-well plates underwent osteoblast differentiation in medium supplemented with KR-12-a6 at 0, 20, 30, 40, 60, or 80 *µ*g/ml at 37°C for 21 days. Then cells were washed in PBS, fixed in 70% ethanol at −20°C for 1 h, and rinsed in dH~2~O. The cultures were stained with 40 mM alizarin red (Sigma-Aldrich; Merck KGaA) at pH 4.2 for 10 min at room temperature with rotation. Cells were then rinsed twice with dH~2~O, followed by washing three times with PBS to reduce nonspecific staining. Images were acquired by an inverted phase contrast microscope (CKX41, Olympus Corporation) under ×100 magnification. At least five fields per sample were randomly selected and observed. For further quantitative analysis, a 10% chlorinated 16 alkyl pyridine solution of sodium phosphate (pH 7.0) was added into each sample to dissolve the dye, and the absorbance was measured at 620 nm by a spectrophotometer.

### RNA isolation and reverse transcription-quantitative PCR (RT-qPCR)

hBMSCs at the density of 5×10^4^ cells/well in 12-well plates were treated with KR-12-a6 at 0, 20, 30, and 40 *µ*g/ml and then cultured at 37°C for 3, 7, and 14 days. On day 3, 7, and 14 post-KR-12-a6 treatment, hBMSCs were harvested in Buffer RLT using an RNeasy Mini kit (Qiagen, Inc.). Total RNA was prepared according to standard protocols. Complementary DNAs (cDNAs) were synthesized from 0.5 µg total RNA using a QuantiTect Reverse Transcription kit (Qiagen, Inc.) according to the manufacturer\'s protocols. qPCR was conducted using a QuantiTect SYBR Green PCR kit (Qiagen, Inc.) and an ABI PRISM 7900HT SDS instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.). qPCR was performed as follows: 2 min activation at 95°C, then 40 cycles of 15 sec denaturation at 95°C and 15 sec annealing at 62°C, and a final 20-sec extension at 68°C. All reactions were in a final volume of 20 µl consisting of 2X master mix (10 µl), forward and reverse primers (2 µl), cDNA, and RNase H~2~O, and each sample was run in triplicate. The specificity of PCR products was confirmed at the end of each run via melting curve analysis. All signals were normalized to *β-actin*, and the quantification cycle was determined. RT-qPCR was quantified by 2^−∆∆Cq^ method ([@b31-mmr-21-01-0061]). Oligonucleotide primers used for RT-qPCR are presented in [Table I](#tI-mmr-21-01-0061){ref-type="table"}. *β-actin* was used as the housekeeping gene to normalize gene expression levels.

### Western blot analysis

hBMSCs at the density of 5×10^4^ cells/well in 12-well plates were treated with KR-12-a6 at 0, 20, 30, and 40 *µ*g/ml and then cultured at 37°C for 7 days. On day 7 post-KR-12-a6 treatment, hBMSCs were harvested and lysed in immunoprecipitation lysis buffer (10 mM Tris, 0.15 M NaCl, 1% NP-40, and 10% glycerol, pH 7.4, at 22°C) containing protease and phosphatase inhibitor cocktails (Sigma-Aldrich; Merck KGaA). Cell lysates were then centrifuged at 15,000 × g for 45 min at 4°C. The supernatants were collected, and the protein concentration was determined by BCA assay with a Bio-Rad Model 680 Plate Reader. Then, 40 µg/sample of protein was separated via 7.5% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with 5% non-fat milk for 1 h at 4°C, and then incubated with primary antibodies targeting phosphorylated (p)-Smad1/5 (cat. no. 9516S, Cell Signaling Technology, 1:500 dilution), Smad1/5 (cat. no. sc-6201, Santa Cruz Biotechnology, 1:200 dilution), or β-actin (cat. no. sc-1616, Santa Cruz Biotechnology, 1:200 dilution) overnight at 4°C. The following day, membranes were washed and incubated with bovine anti-rabbit IgG-HRP secondary antibody (cat. no. sc-2370, Santa Cruz Biotechnology, 1:1,000 dilution) or bovine anti-goat IgG-HRP secondary antibody (cat. no. sc-2350, Santa Cruz Biotechnology, 1:1,000 dilution) for 1 h at room temperature, and immunoreactive bands were detected and visualized by ECL reagent (EMD Millipore) and a FluorChem FC Imaging system (Alpha Innotech). The protein expression was then quantified by AlphaEase FC StandAlone software (version 6.0.0.14, Alpha Innotech).

### LDN-212854 treatment of hBMSCs

hBMSCs at the density of 5×10^4^ cells/well in 12-well plates were pre-treated with 10 µM LDN-212854 (Selleck Chemicals, Shanghai) or DMSO (vehicle control) at 37°C for 14 h, then washed 3 times with plain culture medium. hBMSCs continued to be cultured in medium containing 1 *µ*M LDN-212854 alone or 1 *µ*M LDN-212854 in combination with 40 *µ*g/ml KR-12-a6 at 37°C for 7 days. After washing for times with PBS, hBMSCs were harvested and subjected to western blot analysis.

### Statistical analysis

Each experiment was repeated at least three times, data are expressed as the mean ± standard deviation. One-way analysis of variance (ANOVA) followed by Tukey\'s post hoc test was used to determine statistical significance. All statistical analyses were performed using SPSS 19.0 (IBM Corp.). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Intensity of ALP and alizarin red staining increases with elevated concentrations of KR-12-a6 in hBMSCs

To determine the effects of KR-12-a6 on the osteogenic differentiation of hBMSCs, ALP staining and alizarin red staining were performed. With increasing concentrations of KR-12-a6, the intensity of ALP ([Fig. 1](#f1-mmr-21-01-0061){ref-type="fig"}) and alizarin red staining ([Fig. 2](#f2-mmr-21-01-0061){ref-type="fig"}) also increased. KR-12-a6 at 40 *µ*g/ml exhibited the strongest effects on both ALP ([Fig. 1](#f1-mmr-21-01-0061){ref-type="fig"}) and alizarin red staining ([Fig. 2](#f2-mmr-21-01-0061){ref-type="fig"}), whereas KR-12-a6 at 60 and 80 µg/ml did not notably increase the staining intensity compared with KR-12-a6 at 40 *µ*g/ml.

### mRNA expression of osteoblastic differentiation-associated genes increases after KR-12-a6 stimulation at different time pointsin hBMSCs

The mRNA expression levels of osteoblastic differentiation-associated genes, including *RUNX2* (encoding runt-related transcription factor 2; [Fig. 3A](#f3-mmr-21-01-0061){ref-type="fig"}), *ALP* ([Fig. 3B](#f3-mmr-21-01-0061){ref-type="fig"}), *COL1A1* (encoding type 1 collagen alpha 1 chain; [Fig. 3C](#f3-mmr-21-01-0061){ref-type="fig"}), *BSP* (encoding bone sialoprotein; [Fig. 3D](#f3-mmr-21-01-0061){ref-type="fig"}), *BMP2* (encoding bone morphogenic protein 2; [Fig. 3E](#f3-mmr-21-01-0061){ref-type="fig"}), *OSX* (encoding osterix; [Fig. 3F](#f3-mmr-21-01-0061){ref-type="fig"}), *OCN* (encoding osteocalcin; [Fig. 3G](#f3-mmr-21-01-0061){ref-type="fig"}) and *OPN* (encoding osteopontin; [Fig. 3H](#f3-mmr-21-01-0061){ref-type="fig"}), were determined via RT-qPCR analysis following treatment of hBMSCs with KR-12-a6 for 3, 7 or 14 days. The mRNA levels of *RUNX2* and *ALP* increased in a dose-dependent manner as early as 3 days post-KR-12-a6 treatment. The mRNA expression of *COL1A1, BSP* and *BMP2* was significantly upregulated from day 7 post-KR-12-a6 treatment compared with the control. In contrast, the mRNA levels of *OSX, OCN* and *OPN* were only significantly upregulated at day 14 following KR-12-a6 stimulation.

### BMP/SMAD signaling is activated during KR-12-a6-induced hBMSC osteogenic differentiation

As a significant elevation of *BMP2* mRNA was observed in [Fig. 3E](#f3-mmr-21-01-0061){ref-type="fig"}, it was next investigated as to whether BMP/SMAD signaling was involved in KR-12-a6-induced hBMSC osteogenic differentiation. The activation of SMAD signaling was examined via western blotting following KR-12-a6-induced hBMSC osteogenesis. The results showed that KR-12-a6 promoted the phosphorylation of Smad1/5 in a dose-dependent manner following 7 days of KR-12-a6 treatment ([Fig. 4A and B](#f4-mmr-21-01-0061){ref-type="fig"}) and exhibited the maximum activation at 40 µg/ml. These results suggested that KR-12-a6 activated BMP/SMAD signaling in a dose-dependent manner.

### Inhibition of BMP/SMAD signaling suppresses KR-12-a6-induced osteogenic differentiation of hBMSCs

To further elucidate the role of BMP/SMAD signaling in osteoblast differentiation, LDN-212854, a novel BMP inhibitor that exhibits greater selectivity for BMP compared with the TGF-β type I receptors, was used to suppress BMP/SMAD signaling. Western blotting was performed to observe the changes of several Smad proteins after 7 days of KR-12-a6 treatment with or without LDN-212854 ([Fig. 5](#f5-mmr-21-01-0061){ref-type="fig"}). The results showed that KR-12-a6 at 40 *µ*g/ml significantly promoted the phosphorylation of Smad1/5 in hBMSCs, which was consistent with the results in [Fig. 4](#f4-mmr-21-01-0061){ref-type="fig"}. However, the use of LDN-212854 significantly reduced Smad1/5 phosphorylation in KR-12-a6-treated hBMSCs ([Fig. 5](#f5-mmr-21-01-0061){ref-type="fig"}). RT-qPCR analysis was then performed to further examine the effects of LDN-212854 ([Fig. 6](#f6-mmr-21-01-0061){ref-type="fig"}). The results showed that LDN-212854, which inhibited BMP/SMAD signaling, significantly suppressed the mRNA expression of several osteoblastic differentiation-associated genes, including *RUNX2* ([Fig. 6A](#f6-mmr-21-01-0061){ref-type="fig"}), *ALP* ([Fig. 6B](#f6-mmr-21-01-0061){ref-type="fig"}), *COL1A1* ([Fig. 6C](#f6-mmr-21-01-0061){ref-type="fig"}), *BSP* ([Fig. 6D](#f6-mmr-21-01-0061){ref-type="fig"}), *BMP2* ([Fig. 6E](#f6-mmr-21-01-0061){ref-type="fig"}), *OSX* ([Fig. 6F](#f6-mmr-21-01-0061){ref-type="fig"}), *OCN* ([Fig. 6G](#f6-mmr-21-01-0061){ref-type="fig"}), and *OPN* ([Fig. 6H](#f6-mmr-21-01-0061){ref-type="fig"}) in hBMSCs at day 7 post-KR-12-a6 treatment. Collectively, these results indicated that BMP/SMAD signaling exerts a positive role in KR-12-a6-induced hBMSC osteogenesis.

Discussion
==========

Bone infection and osteolysis are common clinical symptoms of osteomyelitis, which requires local or systemic treatment with antibiotics ([@b32-mmr-21-01-0061]). With the rise of drug-resistant bacteria in clinical bone infection, traditional antibiotics have become less effective ([@b18-mmr-21-01-0061]--[@b20-mmr-21-01-0061]). Due to their low drug resistance and excellent antimicrobial properties, AMPs have received increasing attention. AMPs are an important part of the innate immune system, and are regarded as potential substitutes for traditional antibiotics ([@b33-mmr-21-01-0061]). Antimicrobial peptide LL-37 is an important antimicrobial substance that is naturally synthesized in the human body ([@b7-mmr-21-01-0061],[@b13-mmr-21-01-0061]). It is the first line of defense against local infection and systemic pathogen invasion; more importantly, it does not lead to bacterial resistance ([@b9-mmr-21-01-0061]). However, because of its long amino acid sequence, LL-37 is difficult to develop as a clinical drug for infectious diseases ([@b10-mmr-21-01-0061],[@b11-mmr-21-01-0061]). As the shortest active fragment of LL-37, KR-12 has the advantages of low cost for synthesis and low cytotoxicity; it is thus predicted to serve an important role in the treatment of infections caused by drug-resistant bacteria ([@b10-mmr-21-01-0061],[@b11-mmr-21-01-0061]). As an analogue of KR-12, KR-12-a6 has the same antibacterial properties, and is also a potential drug for the clinical treatment of osteomyelitis ([@b15-mmr-21-01-0061]).

Antibiotics that are commonly used to control infection do not promote the formation of new bones; rather, they inhibit the local osteogenic microenvironment and show no effect on the clinical treatment of infection-associated osteolysis ([@b19-mmr-21-01-0061],[@b20-mmr-21-01-0061]). Studies have shown that antibiotics, including gentamicin and vancomycin, inhibit osteoblast proliferation and differentiation ([@b19-mmr-21-01-0061],[@b20-mmr-21-01-0061]). In contrast, certain small peptides can control infection while promoting new bone formation ([@b21-mmr-21-01-0061]). Various small AMPs and their analogues may have the ability to promote bone differentiation while also possessing antibacterial properties. Therefore, treating osteomyelitis with AMPs may promote bone repair following infection-induced osteolysis while also controlling the infection. Due to the ability to differentiate into osteoblasts, hBMSCs have been widely used in the study of osteogenic differentiation ([@b24-mmr-21-01-0061]). To verify whether KR-12-a6, a KR-12 analogue, can also affect the osteogenic differentiation of hBMSCs, primary hBMSCs were selected as experimental subjects in this study.

The results showed that KR-12-a6 enhanced the osteogenic differentiation and mineralization of hBMSCs in a dose-dependent manner. KR-12-a6 at 40 µg/ml significantly promoted osteogenic differentiation, indicating that KR-12-a6can effectively promote osteogenic differentiation at high concentrations. To accurately evaluate the expression levels of osteoblast-associated genes after KR-12-a6 stimulation, several osteoblast-associated genes were detected at different stages of osteogenic differentiation. During the first 7 days of osteogenesis, the mRNA levels of *RUNX2, ALP, COL1A1, BSP* and *BMP2* increased significantly. In contrast, the late-stage markers of osteogenesis, including *OSX, OCN* and *OPN*, were upregulated during the second week of osteogenic differentiation. RT-qPCR analysis at different stages revealed that KR-12-a6 enhanced the expression of osteoblast-associated genes in hBMSCs; these effects were more notable at high concentrations of KR-12-a6. These findings suggested that KR-12-a6 may promote the osteogenic differentiation of hBMSCs *in vitro*. Further mechanistic studies revealed that KR-12-a6 significantly promoted the phosphorylation of Smad1/5. When LDN-212854, a selective BMP inhibitor, was used to block BMP/SMAD signaling, the activation of p-Smad1/5 was suppressed. Furthermore, the mRNA expression of several osteogenic differentiation-associated genes was also inhibited in KR-12-a6-treated hBMSCs, suggesting the involvement of BMP/SMAD signaling in the KR-12-a6-induced osteogenic differentiation of hBMSCs. However, the current study showed certain limitations. First, results obtained with the use of primary hBMSCs could not fully represent the biophysiological events that happen *in vivo* and the translational relevance of the study should be strictly confirmed in animal studies *in vivo*. Second, the activation of BMP/SMAD signaling might not be the only mechanism through which KR-12-a6 enhanced osteogenesis, other potential signaling pathways involved in osteogenesis should also be investigated.

In conclusion, KR-12-a6 promoted the osteogenic differentiation of hBMSCs in a dose-dependent manner, and BMP/SMAD signaling was involved in the process. In addition, considering the potential for the use of AMPs in the treatment of osteomyelitis and other infections, discovering more peptides with antibacterial properties and bone formation regulation is of clear importance for clinical treatment. KR-12-a6 may be an effective drug for the prevention and treatment of local osteomyelitis and infectious osteolysis.
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![Osteogenic ALP staining of hBMSCs and quantitative analysis following KR-12-a6 treatment. ALP staining was performed following KR-12-a6 stimulation at different concentrations (0, 20, 30, 40, 60, and 80 µg/ml) in hBMSCs. (A) Representative images following stimulation with 0, 20, and 40 µg/ml KR-12-a6. (B) Optical density of staining at 405 nm. Data are presented asthe mean ± SD (n=4). \*P\<0.05, \*\*P\<0.01 vs. KR-12-a6 at 0 µg/ml. Scale bar=100 µm. ALP, alkaline phosphate; OD, optical density; hBMSC, human bone marrow mesenchymal stem cell.](MMR-21-01-0061-g00){#f1-mmr-21-01-0061}

![Osteogenic alizarin red staining of hBMSCs and quantitative analysis following KR-12-a6 treatment. Alizarin red staining was performed following KR-12-a6 stimulation at different concentrations (0, 20, 30, 40, 60, and 80 µg/ml) in hBMSCs. (A) Representative images following stimulation with 0, 20, and 40 µg/ml KR-12-a6. (B) Optical density of staining at 620 nm. Data are presented as the mean ± SD (n=4). \*P\<0.05, \*\*P\<0.01 vs. KR-12-a6 at 0 µg/ml. Scale bar=100 µm. OD, optical density; hBMSC, human bone marrow mesenchymal stem cell.](MMR-21-01-0061-g01){#f2-mmr-21-01-0061}

![Effects of KR-12-a6 on the mRNA expression of osteogenic differentiation markers. Human bone marrow mesenchymal stem cells were treated with KR-12-a6 at concentrations of 0, 20, 30 or 40 µg/ml, and the mRNA levels of (A) *RUNX2*, (B) *ALP*, (C) *COL1A1*, (D) *BSP*, (E) *BMP2*, (F) *OSX*, (G) *OCN* and (H) *OPN* were determined via reverse transcription-quantitative PCR on days 3, 7 and 14 post-KR-12-a6 treatment. Data are presented as the mean ± SD (n=4). \*P\<0.05, \*\*P\<0.01 vs. KR-12-a6 at 0 µg/ml. *ALP*, alkaline phosphatase; *BMP*, bone morphogenic protein; *BSP*, bone sialoprotein; *COL1A1*, type 1 collagen α1 chain; *OCN*, osteocalcin; *OPN*, osteopontin; *OSX*, osterix; *RUNX2*, runt-related transcription factor 2.](MMR-21-01-0061-g02){#f3-mmr-21-01-0061}

![Effects of KR-12-a6 on the activation of BMP/SMAD signaling during the osteogenic differentiation of human bone marrow mesenchymal stem cells. (A) Western blotting was performed to determine the protein expression of p-Smad1/5 and Smad1/5 after 7 days of KR-12-a6 treatment at different concentrations (0, 20, 30 and 40 µg/ml). β-actin served as the loading control. (B) Quantitative analysis of Smad1/5 phosphorylation. Data are presented as the mean ± SD (n=4). \*\*P\<0.01 vs. KR-12-a6 at 0 µg/ml. p, phosphorylated.](MMR-21-01-0061-g03){#f4-mmr-21-01-0061}

![Effects of LDN-212854 on the activation of BMP/SMAD signaling in KR-12-a6-treated hBMSCs. hBMSCs were divided into four treatment groups as follows: Control, KR-12-a6, LDN-212854, and KR-12-a6+LDN-212854. (A) Western blot analysis of the protein expression of p-Smad1/5 and Smad1/5 in the different treatment groups. β-actin served as the loading control. (*B*) Quantitative analysis of Smad1/5 phosphorylation. Data are presented as the mean ± SD (n=4). \*\*P\<0.01 vs. KR-12-a6 at 40 µg/ml without LDN-212854. hBMSC, human bone marrow mesenchymal stem cell; p, phosphorylated.](MMR-21-01-0061-g04){#f5-mmr-21-01-0061}

![Effects of LDN-212854 on the mRNA expression of osteogenic differentiation-associated genes in KR-12-a6-treated hBMSCs. Reverse transcription-quantitative PCR was performed to examine them RNA expression of (A) *RUNX2*, (B) *ALP*, (C) *COL1A1*, (D) *BSP*, (E) *BMP2*, (F) *OSX*, (G) *OCN* and (H) *OPN* in hBMSCs on day 7 following the various treatments: Control, KR-12-a6, LDN-212854, and KR-12-a6+LDN-212854. Data are presented as the mean ± SD (n=4). \*\*P\<0.01 vs. KR-12-a6 at 40 µg/ml without LDN-212854. *ALP*, alkaline phosphatase; *BMP*, bone morphogenic protein; *BSP*, bone sialoprotein; *COL1A1*, type 1 collagen alpha 1 chain; hBMSC, human bone marrow mesenchymal stem cell; *OCN*, osteocalcin; *OPN*, osteopontin; *OSX*, osterix; *RUNX2*, runt-related transcription factor 2.](MMR-21-01-0061-g05){#f6-mmr-21-01-0061}

###### 

Primer sequences for reverse transcription-quantitative PCR.

  Gene        Forward primer                  Reverse primer
  ----------- ------------------------------- ------------------------------------
  *RUNX2*     5′-GCCACCACTCACTACCACACCTA-3′   5′-TCCTGACGAAGTGCCATAGTAGAGATAT-3′
  ALP         5′-GGACCATTCCCACGTCTTCAC-3′     5′-CCTTGTAGCCAGGCCCATTG-3′
  *COL1A1*    5′-TGGGAGGAAGCAAAAGACTC-3′      5′-GGGTCATTTCCACATGCTTT-3′
  *BSP*       5′-TGCCTTGAGCCTGCTTCC-3′        5′-GCAAAATTAAAGCAGTCTTCATTTTG-3′
  *BMP2*      5′-AACACTGTGCGCAGCTTCC-3′       5′-CTCCGGGTTGTTTTCCCAC-3′
  *OSX*       5′-CCCCACCTCTTGCAACCA-3′        5′-CCCCACCTATTGCAACCA-3′
  *OPN*       5′-GCCGACCAAGGAAAACTCACT-3′     5′-GGCACAGGTGATGCCTAGGA-3′
  *OCN*       5′-CCCAGGCGCTACCTGTATCAA-3′     5′-GGTCAGCCAACTCGTCACAGTC-3′
  *β-actin*   5′-TGGCACCCAGCACAATGAA-3′       5′-CTAAGTCATAGTCCGCCTAGAAGCA-3′

*ALP*, alkaline phosphatase; *BMP*, bone morphogenic protein; *BSP*, bone sialoprotein; *COL1A1*, type 1 collagen α1 chain; *OCN*, osteocalcin; *OPN*, osteopontin; *OSX*, osterix; *RUNX2*, runt-related transcription factor 2.

[^1]: Contributed equally
